BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA Warns Covidien plc (COV) Over Surgical-staple Deaths


6/28/2012 8:10:46 AM

Boston Business Journal by Julie M. Donnelly, Reporter

The U.S. Food and Drug Administration (FDA) has sent a warning letter to Covidien plc (NYSE: COV) saying the company has failed to address serious concerns about its Duet Tissue Reinforcement System (TRS) Reload, a medical device which includes surgical staples.

Covidien recalled its Duet surgical staples devices in January, after the company received reports of 13 serious injuries and three deaths. The FDA says that among other violations, Covidien, with U.S. headquarters in Mansfield, Mass., failed to document investigations into the deaths and injuries, and also failed to put into place a corrective action plan in a timely fashion, despite first receiving complaints in 2009.

The FDA says it inspected a Covidien plant in North Haven, Conn. between January 13, 2012, through February 09, 2012, and found a number of violations. The FDA called inadequate the company’s responses to a previous warning letter detailing the violations.

The agency says Covidien failed to initiate a corrective and preventative action (CAPA) plan for the device in a timely fashion. The letter reads in part:

“Despite receiving numerous complaints, adverse event, and serious adverse event information since May of 2009 regarding use of the DUET TRS, a CAPA investigation was not initiated until January 19, 2012 and after the FDA inspection team requested to review the CAPA file related to these complaints and adverse events.”

“Despite receiving numerous complaints, adverse event, and serious adverse event information since May of 2009 regarding use of the DUET TRS, a CAPA investigation was not initiated until January 19, 2012 and after the FDA inspection team requested to review the CAPA file related to these complaints and adverse events.”

The FDA said Covidien’s response, that the company believed that a corrective plan was not required in accordance with the firm’s standard operating procedures, was not adequate. According to the letter, Covidien "did not provide a description or evidence of implementation of a correction or corrective action, including retrospective review of complaints to ensure that documented corrective actions were implemented, for the complaints received for abdominal indications of use for similar patient injuries/deaths."

The company was warned that “failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice,” including seizure, injunction of civil money penalties.

"Covidien is working to address the FDA’s concerns related to our North Haven, Connecticut facility and the DUET TRS product manufactured there," Covidien spokesman Bruce Farmer wrote in an email. "We will respond to the FDA within the specified timeframe and address these issues in a timely manner."




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES